| Question 1: The output stability of mobile LINACs (i.e. Mobetron) is expected to be? |
| Reference: | 1. Beddar AS. Stability of a mobile electron linear accelerator system for intraoperative radiation therapy. Med Phys 32(10):3128-3131, 10/2005.
2. Wootton LS, Meyer J, Kim E, Phillips M. Commissioning, clinical implementation, and performance of the Mobetron2000 for intraoperative radiation therapy, J Appl Clin Med Phys:18: 230–242, 2017.
|
| Choice A: | Comparable to conventional LINACs. |
| Choice B: | Superior than conventional LINACs. |
| Choice C: | Within ± 2 %. |
| Choice D: | Fluctuating anywhere between ± 5 %. |
| Question 2: Traditionally, IORT procedures performed under the Radiation Therapy Oncology Group protocol have specified that the 90% isodose line covers the target volume, whereas the International Commission on Radiation Units (ICRU) and Measurements Report 35 recommends that the dose be prescribed at dmax. What is the recommendation of the AAPM Task Group 48?
|
| Reference: | Beddar AS, Biggs PJ, Chang S, EzzellGA, FaddegonBA, Hensley FW, Mills MD. Intraoperative radiation therapy using mobile electron linear accelerators: Report of AAPM Radiation Therapy Committee Task Group No. 72. Med Phys 33(5):1476-1489, 5/2006.
|
| Choice A: | The 90% dose. |
| Choice B: | At dmax. |
| Choice C: | Both at the 90% dose and the maximum dose dmax. |
| Question 3: At 10 mm depth, 50 kV IB-IORT dose will drop to? |
| Reference: | Eaton DJ, Duck S: Dosimetry measurements with an intra-operative x-ray device. Phys Med Biol 55:N359-69, 2010
|
| Choice A: | 35% |
| Choice B: | 50% |
| Choice C: | 90% |
| Choice D: | 10% |
| Question 4: The TARGIT-A trial stated the typical IORT prescription is?
|
| Reference: | Khan F. M. The Physics of Radiation Therapy 4th Edition 2010, page 316
|
| Choice A: | 34 Gy at surface of the tumor. |
| Choice B: | 34 Gy at 1 cm depth. |
| Choice C: | 20 Gy at surface of the tumor. |
| Choice D: | 20 Gy at 1 cm depth. |
| Question 5: What is the extent of time, in days, required to deliver 88% of the dose from a Pd-103 permanent implant (T1/2=17 days)?
|
| Reference: | Khan F. M. The Physics of Radiation Therapy 4th Edition 2010, page 316. |
| Choice A: | 34 days |
| Choice B: | 51 days |
| Choice C: | 68 days |
| Question 6: The graphic below depicts the isodose distribution around a single Civa dot radioactive source. What is the shielding factor at a distance of 1.0 cm from the source?
|
| Reference: | |
| Choice A: | 10 |
| Choice B: | 13 |
| Choice C: | 21 |
| Choice D: | 33 |
